
Tonix Pharmaceuticals Holding (TNXP) Stock
Tonix Pharmaceuticals Holding Chart
Company Profile
Price: $12.85
Market Cap: $71.84M
Exchange: NASDAQ
CEO: Dr. Seth Lederman M.D.
Sector: Healthcare
Industry: Biotechnology
Employees: -0.00B
Headquarters: Chatham, NJ
Website: Tonix Pharmaceuticals Holding
Business Summary
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
Tonix Pharmaceuticals Holding News
Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases
Results from the Phase 1 single ascending dose study support proceeding to develop a Phase 2 trial for the prevention of kidney transplant rejection

Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference
CHATHAM, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at the BIO CEO & Investor Conference on February 10, 2025, at 1:45 p.m. ET in New York City.

Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer
Ms. Fogarty has served at Tonix since 2016, most recently as Executive Vice President, Product Development Tonix is Preparing for Potential Launch of TNX-102 SL for the management of fibromyalgia with U.S. FDA PDUFA goal date of August 15, 2025 CHATHAM, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the promotion of Siobhan Fogarty to Chief Technical Officer (CTO), effective immediately.

Tonix Pharmaceuticals Announces 1-for-100 Reverse Stock Split
CHATHAM, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it will effect a 1-for-100 reverse stock split of its outstanding common stock. The reverse stock split will be effective for trading purposes as of the commencement of trading on February 5, 2025.

Is Tonix Pharmaceuticals the Next Biotech Breakout?
Clinical-stage biopharmaceutical company Tonix Pharmaceuticals NASDAQ: TNXP is gaining significant attention from investors and market participants. The company develops therapies for conditions with high unmet needs, with a focus on pain management, CNS disorders, and public health vaccines.

Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research.

Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference
CHATHAM, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present and conduct investor meetings at NobleCon20, Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference, being held December 3-4 in Boca Raton, Fla.

Muscarinic Acetylcholine Receptor M1 Antagonists Pipeline Research Report 2024: Comprehensive Insights on 8+ Drugs Featuring Tonix Pharmaceuticals, BMS, WinSanTor, and Apnimed
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Muscarinic Acetylcholine Receptor M1 Antagonists - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 5+ companies and 8+ pipeline drugs in Muscarinic Acetylcholine Receptor M1 Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual
CHATHAM, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the Winter 2024 Investor Summit Virtual on Thursday, November 21, 2024, at 10:00 a.m. ET.

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research.

Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting
CHATHAM, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will deliver a poster presentation at the ACR Convergence 2024 Annual Meeting, which will be held in Washington, D.C., November 14-19, 2024. A copy of the Company's presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the ACR website here.

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company's Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals
The World Health Organization (WHO) declared the spread of new Clade Ib Mpox a public health emergency of international concern (PHEIC): Second Mpox-related WHO PHEIC declaration in two years

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024
New data show tolerability and no evidence of spreading to blood or tissues even at high doses of Tonix's attenuated live-virus, minimally replicating vaccine candidate TNX-801 in immunocompromised animals

Tonix Pharmaceuticals to Present at BIO-Europe® 2024
CHATHAM, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at BIO-Europe®, being held November 4-6, 2024, in Stockholm, Sweden. The presentation will take place on Monday, November 4, 2024, at 1:00 p.m. CET.

Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference
CHATHAM, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Wednesday, October 30, 2024, at 9:30 a.m. ET, and host investor meetings. The conference is being held at the Mandarin Oriental, New York in New York City.

Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA)
NDA based on two Phase 3 studies of TNX-102 SL in fibromyalgia with statistically significant results on the primary endpoint of reducing widespread pain; generally well tolerated

Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals
AI (Artificial Intelligence) and ML (Machine Learning) drug discovery collaboration will accelerate the development of small molecules as orally available host-targeted broad-spectrum medical countermeasures

The Rush for Non-Addictive Painkillers to Counter the Opioid Crisis Puts Two Companies Close to FDA Decisions
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research.

Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat Migraines
New patent expected to provide market exclusivity into 2036 Zembrace® SymTouch® (sumatriptan succinate injection) 10mg is indicated for the acute treatment of migraine in adults CHATHAM, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the United States Patent and Trademark Office issued U.S. Patent No.

Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines
New patent expected to expire in 2030 Tosymra® (sumatriptan nasal spray) 10mg is indicated and marketed for the acute treatment of migraine in adults CHATHAM, N.J., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the United States Patent and Trademark Office issued U.S. Patent No.

New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research.

Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO's Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency
The World Health Organization (WHO) released its preferred target product profile (TPP) criteria for mpox vaccines at its Mpox Research and Innovation Scientific Conference held August 29-30

Tonix Pharmaceuticals Launches National Awareness Campaign on the Impact of Gastroparesis or Stomach Paralysis on the Absorption of Oral Migraine Medications at PAINWeek
Gastroparesis slows the ability of the stomach to empty into the small intestine and thereby can delay absorption of oral medications into the bloodstream

As Research into Pain Accelerates, a Newly Recognized Type of Pain Comes to the Forefront - Tonix Targets it with FDA-Fast Track-Designated TNX-102 SL
CHATHAM, NJ / ACCESSWIRE / September 4, 2024 / This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research.

Tonix Pharmaceuticals Presented Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium (MHSRS)
Investigator-initiated Phase 2 trial to evaluate TNX-102 SL's potential to reduce severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD) and posttraumatic stress disorder (PTSD) expected to begin third quarter 2024

Tonix Pharmaceuticals Holding Earnings
This section highlights Tonix Pharmaceuticals Holding's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
---|
Financial Statements
Access annual & quarterly financial statements for Tonix Pharmaceuticals Holding, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|
Revenue | $7.77M | $- | $- | $- | $- |
Cost of Revenue | $4.74M | $112.09M | $92.31M | $50.51M | $28.83M |
Gross Profit | $3.03M | $-112.09M | $-92.31M | $-50.51M | $-28.83M |
Gross Profit Ratio | 38.97% | 0.00% | 0.00% | 0.00% | 0.00% |
Research and Development Expenses | $86.66M | $81.88M | $68.84M | $36.16M | $18.19M |
General and Administrative Expenses | $34.75M | $30.21M | $23.47M | $14.35M | $10.64M |
Selling and Marketing Expenses | $- | $- | $- | $- | $- |
Selling General and Administrative Expenses | $34.75M | $30.21M | $23.47M | $14.35M | $10.64M |
Other Expenses | $- | $- | $- | $- | $- |
Operating Expenses | $121.41M | $112.09M | $92.31M | $50.51M | $28.83M |
Cost and Expenses | $126.15M | $112.09M | $92.31M | $50.51M | $28.83M |
Interest Income | $- | $1.87M | $25.00K | $48.00K | $210.00K |
Interest Expense | $- | $- | $- | $- | $- |
Depreciation and Amortization | $4.29M | $1.25M | $50.00K | $27.00K | $26.00K |
EBITDA | $-114.09M | $-110.84M | $-92.26M | $-50.48M | $-28.80M |
EBITDA Ratio | -1468.70% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | $-118.38M | $-112.09M | $-92.31M | $-50.51M | $-28.83M |
Operating Income Ratio | -1523.94% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income Expenses Net | $1.72M | $1.87M | $25.00K | $48.00K | $210.00K |
Income Before Tax | $-116.66M | $-110.22M | $-92.29M | $-50.46M | $-28.62M |
Income Before Tax Ratio | -1501.78% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | $- | $4.79M | $-75.00K | $-75.00K | $-236.00K |
Net Income | $-116.66M | $-116.88M | $-92.29M | $-52.17M | $-31.09M |
Net Income Ratio | -1501.78% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | $-219.09 | $-640.26 | $-1620.86 | $-3530.04 | $0.00 |
EPS Diluted | $-219.09 | $-640.26 | $-1620.86 | $-3530.04 | $0.00 |
Weighted Average Shares Outstanding | 532.48K | 182.54K | 56.94K | 14.78K | - |
Weighted Average Shares Outstanding Diluted | 532.48K | 182.54K | 56.94K | 14.78K | - |
SEC Filing | Source | Source | Source | Source | Source |
Income Statement Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $2.82M | $2.21M | $2.48M | $3.78M | $3.99M | $- | $33.90M | $- | $- | $9.03M | $- | $- | $- | $- | $- | $2.91M | $- | $- | $- | $--0.00B |
Cost of Revenue | $1.55M | $3.37M | $1.66M | $3.86M | $2.37M | $29.00M | $893.00K | $836.00K | $- | $102.00K | $63.00K | $27.00K | $18.54M | $23.56M | $20.74M | $- | $12.00M | $14.19M | $7.30M | $- |
Gross Profit | $1.27M | $-1.16M | $822.00K | $-79.00K | $1.61M | $-29.00M | $33.01M | $-836.00K | $- | $8.93M | $-63.00K | $-27.00K | $-18.54M | $-23.56M | $-20.74M | $2.91M | $-12.00M | $-14.19M | $-7.30M | $--0.00B |
Gross Profit Ratio | 44.90% | -52.49% | 33.12% | -2.09% | 40.49% | 0.00% | 97.37% | 0.00% | 0.00% | 98.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% |
Research and Development Expenses | $9.11M | $9.70M | $12.86M | $17.12M | $21.05M | $21.98M | $26.51M | $24.67M | $22.20M | $16.58M | $18.42M | $22.30M | $13.08M | $18.13M | $15.33M | $12.10M | $8.81M | $10.57M | $4.68M | $5.69M |
General and Administrative Expenses | $- | $7.50M | $9.31M | $11.62M | $8.71M | $7.03M | $7.39M | $8.05M | $7.39M | $6.76M | $8.01M | $7.26M | $5.45M | $5.43M | $5.41M | $4.93M | $3.19M | $3.62M | $2.62M | $3.04M |
Selling and Marketing Expenses | $- | $- | $- | $-1.49M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Selling General and Administrative Expenses | $7.71M | $7.50M | $9.31M | $10.13M | $8.71M | $7.03M | $7.39M | $8.05M | $7.39M | $6.76M | $8.01M | $7.26M | $5.45M | $5.43M | $5.41M | $4.93M | $3.19M | $3.62M | $2.62M | $3.04M |
Other Expenses | $- | $- | $-593.00K | $- | $- | $646.00K | $897.00K | $- | $- | $- | $- | $29.48M | $- | $- | $- | $- | $- | $- | $- | $- |
Operating Expenses | $16.82M | $17.20M | $22.17M | $27.25M | $29.76M | $29.00M | $33.90M | $32.73M | $29.59M | $23.34M | $26.44M | $29.56M | $18.54M | $23.56M | $20.74M | $17.02M | $12.00M | $14.19M | $7.30M | $8.73M |
Cost and Expenses | $18.38M | $20.57M | $23.83M | $31.11M | $32.14M | $29.00M | $33.90M | $32.73M | $29.59M | $23.34M | $26.44M | $29.56M | $18.54M | $23.56M | $20.74M | $17.02M | $12.00M | $14.19M | $7.30M | $8.73M |
Interest Income | $- | $- | $- | $- | $172.00K | $646.00K | $897.00K | $1.05M | $610.00K | $196.00K | $19.00K | $7.00K | $7.00K | $9.00K | $83.00K | $2.00K | $9.00K | $13.00K | $24.00K | $27.00K |
Interest Expense | $- | $- | $- | $- | $- | $- | $- | $- | $- | $196.00K | $19.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Depreciation and Amortization | $510.00K | $1.21M | $1.21M | $1.49M | $978.00K | $900.00K | $893.00K | $836.00K | $252.00K | $102.00K | $63.00K | $27.00K | $10.00K | $7.00K | $6.00K | $7.00K | $8.00K | $6.00K | $6.00K | $5.00K |
EBITDA | $-13.38M | $-17.39M | $-20.38M | $-25.83M | $-27.00M | $-28.08M | $-33.01M | $-31.89M | $-29.34M | $-23.23M | $-26.37M | $-29.45M | $-18.52M | $-23.55M | $-20.73M | $-17.02M | $-11.99M | $-14.19M | $-7.29M | $-8.73M |
EBITDA Ratio | -473.99% | -787.68% | -860.23% | -683.73% | -705.62% | 0.00% | -100.00% | 0.00% | 0.00% | -258.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -584.18% | 0.00% | 0.00% | 0.00% | 1746800.00% |
Operating Income | $-15.55M | $-18.36M | $-21.35M | $-27.33M | $-28.15M | $-29.00M | $-33.90M | $-32.73M | $-29.59M | $-23.34M | $-26.40M | $-29.56M | $-18.54M | $-23.56M | $-20.74M | $-17.02M | $-12.00M | $-14.19M | $-7.30M | $-8.73M |
Operating Income Ratio | -551.17% | -831.48% | -860.23% | -723.18% | -705.62% | 0.00% | -100.00% | 0.00% | 0.00% | -258.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -584.18% | 0.00% | 0.00% | 0.00% | 1746800.00% |
Total Other Income Expenses Net | $1.34M | $-60.42M | $6.41M | $7.00K | $172.00K | $646.00K | $897.00K | $1.05M | $610.00K | $196.00K | $19.00K | $-74.00K | $7.00K | $9.00K | $83.00K | $2.00K | $9.00K | $13.00K | $24.00K | $27.00K |
Income Before Tax | $-14.21M | $-78.78M | $-14.94M | $-27.32M | $-27.98M | $-28.36M | $-33.01M | $-31.68M | $-28.98M | $-23.14M | $-26.42M | $-29.55M | $-18.53M | $-23.55M | $-20.65M | $-17.02M | $-11.99M | $-14.18M | $-7.27M | $-8.71M |
Income Before Tax Ratio | -503.65% | -3567.75% | -601.89% | -723.00% | -701.30% | 0.00% | -97.35% | 0.00% | 0.00% | -256.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -584.11% | 0.00% | 0.00% | 0.00% | 1741400.00% |
Income Tax Expense | $- | $- | $-1.21M | $--0.00B | $-1.22M | $29.00M | $-1.79M | $5.61M | $- | $-196.00K | $-19.00K | $-92.42M | $- | $- | $--0.00B | $-7.00K | $- | $- | $- | $-5.00K |
Net Income | $-14.21M | $-78.78M | $-14.94M | $-27.32M | $-27.98M | $-28.36M | $-33.01M | $-34.08M | $-28.98M | $-27.39M | $-26.42M | $-29.55M | $-18.53M | $-23.55M | $-20.65M | $-17.02M | $-11.99M | $-14.18M | $-8.98M | $-11.18M |
Net Income Ratio | -503.65% | -3567.75% | -601.89% | -723.00% | -701.30% | 0.00% | -100.00% | 0.00% | 0.00% | -254.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -584.11% | 0.00% | 0.00% | 0.00% | 1741400.00% |
EPS | $-0.23 | $-19.28 | $-5.91 | $-27.53 | $-58.40 | $-85.71 | $-102.85 | $-111.06 | $-4.24 | $-244.55 | $-321.28 | $-419.18 | $-319.96 | $-449.35 | $-455.62 | $-664.75 | $-603.27 | $0.00 | $0.00 | $0.00 |
EPS Diluted | $-0.23 | $-19.28 | $-5.91 | $-27.53 | $-58.40 | $-85.71 | $-102.85 | $-111.06 | $-4.24 | $-244.55 | $-321.28 | $-419.18 | $-319.96 | $-449.35 | $-455.62 | $-664.75 | $-603.27 | $0.00 | $0.00 | $0.00 |
Weighted Average Shares Outstanding | 62.12M | 4.09M | 2.53M | 992.40K | 478.99K | 330.85K | 320.89K | 306.90K | 6.84M | 112.02K | 82.22K | 70.50K | 57.91K | 52.42K | 45.33K | 25.61K | 19.88K | - | - | - |
Weighted Average Shares Outstanding Diluted | 62.12M | 4.09M | 2.53M | 992.40K | 478.99K | 330.85K | 320.89K | 306.90K | 6.84M | 112.02K | 82.22K | 70.50K | 57.91K | 52.42K | 45.33K | 25.61K | 19.88K | - | - | - |
SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|
Cash and Cash Equivalents | $24.95M | $120.23M | $178.66M | $77.07M | $11.25M |
Short Term Investments | $- | $- | $- | $- | $- |
Cash and Short Term Investments | $24.95M | $120.23M | $178.66M | $77.07M | $11.25M |
Net Receivables | $4.59M | $- | $7.73M | $7.63M | $- |
Inventory | $14.15M | $-8.04M | $-7.73M | $-7.63M | $-1.01M |
Other Current Assets | $4.08M | $10.55M | $2.66M | $3.29M | $1.69M |
Total Current Assets | $47.77M | $130.78M | $189.05M | $87.99M | $13.95M |
Property Plant Equipment Net | $94.85M | $94.53M | $51.47M | $9.83M | $390.00K |
Goodwill | $965.00K | $- | $- | $- | $- |
Intangible Assets | $9.74M | $120.00K | $- | $120.00K | $120.00K |
Goodwill and Intangible Assets | $10.71M | $120.00K | $120.00K | $120.00K | $120.00K |
Long Term Investments | $- | $241.00K | $240.00K | $240.00K | $100.00K |
Tax Assets | $- | $-120.00K | $-240.00K | $-240.00K | $-100.00K |
Other Non-Current Assets | $1.13M | $143.00K | $259.00K | $245.00K | $100.00K |
Total Non-Current Assets | $106.69M | $94.91M | $51.85M | $10.19M | $610.00K |
Other Assets | $- | $- | $- | $- | $- |
Total Assets | $154.46M | $225.69M | $240.90M | $98.18M | $14.56M |
Account Payables | $3.78M | $8.07M | $13.28M | $4.60M | $3.07M |
Short Term Debt | $2.62M | $432.00K | $489.00K | $595.00K | $352.00K |
Tax Payables | $- | $- | $- | $- | $- |
Deferred Revenue | $2.98M | $3.27M | $2.83M | $2.17M | $704.00K |
Other Current Liabilities | $9.50M | $6.41M | $5.11M | $2.46M | $1.01M |
Total Current Liabilities | $18.88M | $18.18M | $21.72M | $9.82M | $5.13M |
Long Term Debt | $7.19M | $328.00K | $467.00K | $716.00K | $6.00K |
Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
Other Non-Current Liabilities | $22.86M | $- | $- | $- | $- |
Total Non-Current Liabilities | $30.05M | $328.00K | $467.00K | $716.00K | $6.00K |
Other Liabilities | $- | $- | $- | $- | $- |
Total Liabilities | $48.93M | $18.51M | $22.18M | $10.54M | $5.14M |
Preferred Stock | $- | $- | $- | $- | $- |
Common Stock | $59.00K | $76.00K | $496.00K | $206.00K | $9.00K |
Retained Earnings | $-600.66M | $-470.04M | $-359.82M | $-267.53M | $-217.07M |
Accumulated Other Comprehensive Income Loss | $-232.00K | $-167.00K | $-92.00K | $-62.00K | $-46.00K |
Other Total Stockholders Equity | $706.36M | $677.31M | $578.61M | $355.04M | $226.52M |
Total Stockholders Equity | $105.53M | $207.18M | $218.72M | $87.65M | $9.42M |
Total Equity | $105.53M | $207.18M | $218.72M | $87.65M | $9.42M |
Total Liabilities and Stockholders Equity | $154.46M | $225.69M | $240.90M | $98.18M | $14.56M |
Minority Interest | $- | $- | $- | $- | $- |
Total Liabilities and Total Equity | $154.46M | $225.69M | $240.90M | $98.18M | $14.56M |
Total Investments | $900.00K | $241.00K | $240.00K | $240.00K | $100.00K |
Total Debt | $9.81M | $760.00K | $956.00K | $1.31M | $358.00K |
Net Debt | $-15.13M | $-119.47M | $-177.70M | $-75.76M | $-10.89M |
Balance Sheet Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash and Cash Equivalents | $28.23M | $4.16M | $7.05M | $24.95M | $6.91M | $25.62M | $71.97M | $120.23M | $139.98M | $145.48M | $140.44M | $178.66M | $182.97M | $165.72M | $164.21M | $77.07M | $55.66M | $55.02M | $30.66M | $11.25M |
Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Cash and Short Term Investments | $28.23M | $4.16M | $7.05M | $24.95M | $6.91M | $25.62M | $71.97M | $120.23M | $139.98M | $145.48M | $140.44M | $178.66M | $182.97M | $165.72M | $164.21M | $77.07M | $55.66M | $55.02M | $30.66M | $11.25M |
Net Receivables | $4.01M | $3.34M | $- | $4.59M | $1.56M | $- | $- | $- | $- | $- | $- | $7.73M | $- | $- | $- | $7.63M | $- | $- | $- | $- |
Inventory | $7.93M | $9.46M | $12.35M | $14.15M | $13.32M | $13.70M | $- | $-8.04M | $- | $- | $- | $-7.73M | $- | $- | $- | $-7.63M | $- | $- | $- | $-1.01M |
Other Current Assets | $10.37M | $8.34M | $10.70M | $2.57M | $9.54M | $12.01M | $11.75M | $10.55M | $22.32M | $46.27M | $25.11M | $2.66M | $12.11M | $11.55M | $8.95M | $3.29M | $6.36M | $2.60M | $2.73M | $1.69M |
Total Current Assets | $50.54M | $25.29M | $30.10M | $47.77M | $31.34M | $51.33M | $83.73M | $130.78M | $151.14M | $191.75M | $152.99M | $189.05M | $195.08M | $177.27M | $173.16M | $87.99M | $62.02M | $57.63M | $33.40M | $13.95M |
Property Plant Equipment Net | $43.38M | $43.94M | $93.81M | $94.85M | $95.95M | $96.93M | $94.98M | $94.53M | $91.15M | $84.04M | $70.35M | $51.47M | $19.30M | $11.51M | $9.99M | $9.83M | $5.24M | $478.00K | $309.00K | $390.00K |
Goodwill | $- | $- | $965.00K | $965.00K | $965.00K | $965.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Intangible Assets | $120.00K | $120.00K | $9.51M | $9.74M | $9.98M | $10.22M | $- | $120.00K | $- | $- | $- | $120.00K | $120.00K | $120.00K | $120.00K | $120.00K | $120.00K | $120.00K | $120.00K | $120.00K |
Goodwill and Intangible Assets | $120.00K | $120.00K | $10.47M | $10.71M | $10.95M | $11.19M | $- | $120.00K | $- | $- | $- | $120.00K | $120.00K | $120.00K | $120.00K | $120.00K | $120.00K | $120.00K | $120.00K | $120.00K |
Long Term Investments | $- | $- | $900.00K | $900.00K | $244.00K | $243.00K | $242.00K | $241.00K | $- | $- | $- | $240.00K | $240.00K | $240.00K | $240.00K | $- | $- | $- | $- | $- |
Tax Assets | $- | $- | $--0.00B | $9.74M | $-244.00K | $-243.00K | $- | $-120.00K | $- | $- | $- | $-240.00K | $-240.00K | $-240.00K | $-240.00K | $- | $- | $- | $- | $- |
Other Non-Current Assets | $951.00K | $961.00K | $60.00K | $-9.51M | $1.05M | $292.00K | $143.00K | $143.00K | $360.00K | $379.00K | $379.00K | $259.00K | $271.00K | $266.00K | $245.00K | $245.00K | $239.00K | $120.00K | $107.00K | $100.00K |
Total Non-Current Assets | $44.45M | $45.02M | $105.24M | $106.69M | $107.94M | $108.41M | $95.36M | $94.91M | $91.51M | $84.42M | $70.73M | $51.85M | $19.69M | $11.90M | $10.36M | $10.19M | $5.60M | $718.00K | $536.00K | $610.00K |
Other Assets | $- | $- | $-0.00B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Assets | $94.99M | $70.31M | $135.34M | $154.46M | $139.28M | $159.74M | $179.09M | $225.69M | $242.65M | $276.17M | $223.72M | $240.90M | $214.77M | $189.16M | $183.52M | $98.18M | $67.62M | $58.34M | $33.93M | $14.56M |
Account Payables | $3.94M | $10.41M | $6.65M | $3.78M | $7.80M | $7.67M | $8.02M | $8.07M | $4.56M | $9.57M | $9.40M | $13.28M | $7.96M | $3.41M | $2.86M | $4.60M | $1.77M | $3.19M | $1.41M | $3.07M |
Short Term Debt | $275.00K | $3.37M | $3.10M | $2.62M | $868.00K | $872.00K | $876.00K | $432.00K | $1.01M | $1.02M | $794.00K | $978.00K | $1.17M | $928.00K | $772.00K | $595.00K | $1.07M | $692.00K | $512.00K | $352.00K |
Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Deferred Revenue | $- | $- | $- | $2.98M | $- | $- | $- | $3.27M | $-504.00K | $- | $- | $2.83M | $- | $- | $- | $2.17M | $- | $- | $- | $704.00K |
Other Current Liabilities | $10.97M | $8.26M | $10.73M | $9.50M | $9.07M | $9.90M | $4.18M | $6.41M | $7.78M | $5.32M | $5.16M | $7.00M | $2.90M | $3.75M | $2.40M | $2.46M | $1.54M | $797.00K | $740.00K | $1.01M |
Total Current Liabilities | $15.18M | $22.04M | $20.48M | $18.88M | $17.73M | $18.44M | $13.07M | $18.18M | $13.34M | $15.91M | $15.35M | $21.72M | $12.03M | $8.08M | $6.03M | $9.82M | $4.38M | $4.68M | $2.66M | $5.13M |
Long Term Debt | $5.60M | $6.16M | $6.72M | $7.19M | $716.00K | $831.00K | $588.00K | $328.00K | $382.00K | $474.00K | $405.00K | $467.00K | $530.00K | $591.00K | $577.00K | $716.00K | $671.00K | $95.00K | $25.00K | $6.00K |
Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-80.00K | $- | $- | $- | $- |
Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-636.00K | $- | $- | $- | $- |
Other Non-Current Liabilities | $- | $- | $- | $22.86M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Non-Current Liabilities | $5.60M | $6.16M | $6.72M | $30.05M | $716.00K | $831.00K | $588.00K | $328.00K | $382.00K | $474.00K | $405.00K | $467.00K | $530.00K | $591.00K | $577.00K | $716.00K | $671.00K | $95.00K | $25.00K | $6.00K |
Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $31.50M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Liabilities | $20.78M | $28.20M | $27.20M | $48.93M | $18.45M | $19.27M | $13.66M | $18.51M | $13.72M | $47.88M | $15.76M | $22.18M | $12.56M | $8.67M | $6.61M | $10.54M | $5.05M | $4.77M | $2.69M | $5.14M |
Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $31.50M | $- | $359.82M | $- | $- | $- | $- | $- | $- | $- | $- |
Common Stock | $156.00K | $10.00K | $74.00K | $59.00K | $18.00K | $11.00K | $64.00K | $76.00K | $53.00K | $32.00K | $553.00K | $496.00K | $404.00K | $346.00K | $324.00K | $206.00K | $140.00K | $105.00K | $49.00K | $9.00K |
Retained Earnings | $-708.59M | $-694.37M | $-615.60M | $-600.66M | $-573.34M | $-545.36M | $-516.99M | $-470.04M | $-438.36M | $-409.38M | $-386.24M | $-359.82M | $-330.27M | $-311.74M | $-288.19M | $-267.53M | $-250.51M | $-238.52M | $-224.34M | $-217.07M |
Accumulated Other Comprehensive Income Loss | $-250.00K | $-243.00K | $-240.00K | $-232.00K | $-220.00K | $-212.00K | $-211.00K | $-167.00K | $-160.00K | $-143.00K | $-118.00K | $-92.00K | $-81.00K | $-71.00K | $-63.00K | $-62.00K | $-64.00K | $-69.00K | $-60.00K | $-46.00K |
Other Total Stockholders Equity | $782.89M | $736.71M | $723.91M | $706.36M | $694.37M | $686.02M | $682.57M | $677.31M | $667.39M | $637.77M | $593.76M | $578.13M | $532.16M | $491.96M | $464.84M | $355.04M | $313.00M | $292.06M | $255.60M | $226.52M |
Total Stockholders Equity | $74.21M | $42.10M | $108.14M | $105.53M | $120.83M | $140.46M | $165.43M | $207.18M | $228.92M | $228.28M | $207.96M | $218.72M | $202.22M | $180.49M | $176.92M | $87.65M | $62.57M | $53.57M | $31.25M | $9.42M |
Total Equity | $74.21M | $42.10M | $108.14M | $105.53M | $120.83M | $140.46M | $165.43M | $207.18M | $228.92M | $228.28M | $207.96M | $218.72M | $202.22M | $180.49M | $176.92M | $87.65M | $62.57M | $53.57M | $31.25M | $9.42M |
Total Liabilities and Stockholders Equity | $94.99M | $70.31M | $135.34M | $154.46M | $139.28M | $159.74M | $179.09M | $225.69M | $242.65M | $276.17M | $223.72M | $240.90M | $214.77M | $189.16M | $183.52M | $98.18M | $67.62M | $58.34M | $33.93M | $14.56M |
Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Liabilities and Total Equity | $94.99M | $70.31M | $135.34M | $154.46M | $139.28M | $159.74M | $179.09M | $225.69M | $242.65M | $276.17M | $223.72M | $240.90M | $214.77M | $189.16M | $183.52M | $98.18M | $67.62M | $58.34M | $33.93M | $14.56M |
Total Investments | $- | $902.00K | $900.00K | $900.00K | $244.00K | $243.00K | $242.00K | $241.00K | $- | $- | $- | $240.00K | $240.00K | $240.00K | $240.00K | $- | $- | $- | $- | $- |
Total Debt | $5.87M | $9.26M | $9.82M | $9.81M | $1.15M | $1.27M | $1.03M | $760.00K | $886.00K | $985.00K | $802.00K | $956.00K | $1.11M | $1.05M | $963.00K | $1.31M | $1.21M | $441.00K | $281.00K | $358.00K |
Net Debt | $-22.36M | $5.10M | $2.77M | $-15.13M | $-5.76M | $-24.35M | $-70.95M | $-119.47M | $-139.09M | $-144.49M | $-139.63M | $-177.70M | $-181.86M | $-164.66M | $-163.25M | $-75.76M | $-54.45M | $-54.58M | $-30.38M | $-10.89M |
Annual Cash Flow
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|
Net Income | $-116.66M | $-110.22M | $-92.29M | $-50.46M | $-28.62M |
Depreciation and Amortization | $4.29M | $1.25M | $50.00K | $27.00K | $26.00K |
Deferred Income Tax | $- | $-14.46M | $- | $- | $154.00K |
Stock Based Compensation | $9.28M | $10.91M | $7.90M | $2.88M | $1.46M |
Change in Working Capital | $-35.00K | $-2.00K | $5.78M | $-2.37M | $452.00K |
Accounts Receivables | $- | $- | $- | $- | $- |
Inventory | $61.00K | $- | $- | $- | $- |
Accounts Payables | $-3.49M | $-1.04M | $3.53M | $1.53M | $1.66M |
Other Working Capital | $3.39M | $1.04M | $2.25M | $-3.89M | $-1.21M |
Other Non Cash Items | $1.12M | $14.46M | $3.00M | $1.36M | $-154.00K |
Net Cash Provided by Operating Activities | $-102.00M | $-98.05M | $-75.56M | $-48.57M | $-26.68M |
Investments in Property Plant and Equipment | $-7.89M | $-48.15M | $-35.31M | $-8.56M | $-17.00K |
Acquisitions Net | $-22.17M | $- | $- | $- | $- |
Purchases of Investments | $- | $- | $- | $- | $- |
Sales Maturities of Investments | $- | $- | $- | $- | $- |
Other Investing Activities | $999.00K | $- | $- | $- | $-17.00K |
Net Cash Used for Investing Activities | $-29.07M | $-48.15M | $-35.31M | $-8.56M | $-17.00K |
Debt Repayment | $8.94M | $- | $- | $- | $- |
Common Stock Issued | $18.94M | $135.09M | $212.39M | $108.61M | $5.84M |
Common Stock Repurchased | $-13.96M | $-47.25M | $- | $- | $- |
Dividends Paid | $- | $-6.66M | $- | $-451.00K | $-2.47M |
Other Financing Activities | $22.60M | $40.00K | $98.00K | $14.95M | $9.55M |
Net Cash Used Provided by Financing Activities | $36.52M | $87.84M | $212.49M | $123.11M | $12.92M |
Effect of Forex Changes on Cash | $-65.00K | $-74.00K | $-31.00K | $-16.00K | $-4.00K |
Net Change in Cash | $-94.62M | $-58.43M | $101.59M | $65.96M | $-13.79M |
Cash at End of Period | $25.85M | $120.47M | $178.90M | $77.31M | $11.35M |
Cash at Beginning of Period | $120.47M | $178.90M | $77.31M | $11.35M | $25.13M |
Operating Cash Flow | $-102.00M | $-98.05M | $-75.56M | $-48.57M | $-26.68M |
Capital Expenditure | $-7.89M | $-48.15M | $-35.31M | $-8.56M | $-17.00K |
Free Cash Flow | $-109.90M | $-146.20M | $-110.86M | $-57.13M | $-26.70M |
Cash Flow Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | $-14.21M | $-78.78M | $-14.94M | $-27.32M | $-27.98M | $-28.36M | $-33.01M | $-31.68M | $-28.98M | $-23.14M | $-26.42M | $-29.55M | $-18.53M | $-23.55M | $-20.65M | $-17.02M | $-11.99M | $-14.18M | $-7.27M | $-8.71M |
Depreciation and Amortization | $510.00K | $1.21M | $1.21M | $1.49M | $1.22M | $921.00K | $893.00K | $836.00K | $252.00K | $102.00K | $63.00K | $27.00K | $10.00K | $7.00K | $6.00K | $7.00K | $8.00K | $6.00K | $6.00K | $5.00K |
Deferred Income Tax | $- | $- | $- | $-9.01M | $- | $-4.54M | $-4.00M | $-8.78M | $- | $-2.38M | $- | $-2.30M | $- | $- | $- | $2.37M | $- | $- | $- | $-452.00K |
Stock Based Compensation | $1.04M | $1.15M | $1.69M | $2.04M | $2.08M | $2.36M | $2.79M | $2.72M | $2.77M | $2.81M | $2.62M | $2.30M | $2.30M | $2.09M | $1.21M | $871.00K | $912.00K | $733.00K | $360.00K | $359.00K |
Change in Working Capital | $-5.89M | $4.82M | $1.17M | $372.37K | $1.49M | $1.70M | $-3.59M | $5.83M | $2.43M | $-946.00K | $-7.31M | $4.79M | $3.27M | $-651.00K | $-1.62M | $2.23M | $-4.21M | $2.04M | $-2.42M | $1.63M |
Accounts Receivables | $-1.64M | $- | $- | $-61.00K | $-1.56M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Inventory | $-385.92K | $1.16M | $1.29M | $61.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Accounts Payables | $-6.25M | $3.73M | $2.98M | $-3.99M | $1.02M | $-1.15M | $575.00K | $3.03M | $-2.52M | $1.55M | $-3.11M | $156.00K | $4.56M | $548.00K | $-1.74M | $2.83M | $-1.42M | $1.78M | $-1.66M | $1.95M |
Other Working Capital | $2.39M | $-64.00K | $-3.10M | $4.36M | $474.00K | $2.85M | $-4.17M | $2.79M | $3.00K | $-2.50M | $-4.20M | $4.63M | $-1.29M | $-1.20M | $116.00K | $-600.00K | $-2.80M | $259.00K | $-757.00K | $-319.00K |
Other Non Cash Items | $-250.13K | $61.68M | $-6.86M | $10.74M | $-196.00K | $4.54M | $4.00M | $8.78M | $-2.45M | $2.38M | $5.86M | $2.30M | $-1.77M | $3.00M | $2.96M | $-2.37M | $-1.43M | $1.36M | $-1.70M | $452.00K |
Net Cash Provided by Operating Activities | $-18.80M | $-9.92M | $-17.57M | $-21.69M | $-23.39M | $-23.37M | $-32.91M | $-22.30M | $-23.54M | $-21.17M | $-31.05M | $-22.45M | $-12.95M | $-19.11M | $-21.06M | $-13.91M | $-15.29M | $-10.04M | $-9.33M | $-6.71M |
Investments in Property Plant and Equipment | $-10.77K | $1.77K | $-108.00K | $-355.65K | $-1.81M | $-1.84M | $-3.80M | $-4.67M | $-8.82M | $-14.44M | $-20.22M | $-25.62M | $-7.75M | $-1.43M | $-505.00K | $-4.53M | $-4.02M | $-14.00K | $- | $-5.00K |
Acquisitions Net | $- | $- | $- | $257.05K | $794.02K | $-22.50M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Other Investing Activities | $1.77K | $- | $- | $7.00K | $197.98K | $324.96K | $- | $- | $- | $- | $- | $25.62M | $- | $- | $- | $- | $- | $- | $- | $-17.00K |
Net Cash Used for Investing Activities | $-9.00K | $1.77K | $-108.00K | $-98.60K | $-821.00K | $-24.02M | $-3.80M | $-4.67M | $-8.82M | $-14.44M | $-20.22M | $-25.62M | $-7.75M | $-1.43M | $-505.00K | $-4.53M | $-4.02M | $-14.00K | $- | $-5.00K |
Debt Repayment | $-705.00K | $-705.00K | $-235.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Common Stock Issued | $43.61M | $10.73M | $23.00K | $9.20M | $6.27M | $1.03M | $2.44M | $9.63M | $26.88M | $44.93M | $13.02M | $43.77M | $37.89M | $22.05M | $108.68M | $39.86M | $17.65M | $34.42M | $16.68M | $965.00K |
Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $-13.96M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $-4.25M | $- | $- | $- | $- | $- | $- | $- | $-451.00K | $- | $- | $-1.26M | $-2.47M |
Other Financing Activities | $4.00K | $-3.11M | $23.00K | $31.51M | $- | $- | $29.00K | $9.08M | $-36.12M | $27.25M | $40.00K | $- | $68.00K | $- | $30.00K | $451.00K | $2.42M | $- | $13.34M | $9.45M |
Net Cash Used Provided by Financing Activities | $42.91M | $6.91M | $-212.00K | $41.29M | $6.27M | $1.03M | $-11.50M | $7.23M | $-4.62M | $72.18M | $13.06M | $43.77M | $37.96M | $22.05M | $108.71M | $39.86M | $20.07M | $34.42M | $28.76M | $7.95M |
Effect of Forex Changes on Cash | $-17.00K | $1.00K | $-4.00K | $-10.00K | $-12.00K | $- | $-43.00K | $-5.00K | $-20.00K | $-24.00K | $-25.00K | $-10.00K | $-13.00K | $-7.00K | $-1.00K | $16.00K | $7.00K | $-8.00K | $-15.00K | $-1.00K |
Net Change in Cash | $24.08M | $-2.89M | $-17.90M | $18.03M | $-17.94M | $-46.36M | $-48.25M | $-19.75M | $-37.00M | $36.54M | $-38.23M | $-4.31M | $17.25M | $1.50M | $87.15M | $21.41M | $775.00K | $24.36M | $19.42M | $1.23M |
Cash at End of Period | $29.14M | $4.16M | $7.05M | $24.95M | $7.92M | $25.86M | $72.22M | $120.47M | $140.22M | $177.22M | $140.68M | $178.90M | $183.21M | $165.96M | $164.45M | $77.31M | $55.90M | $55.12M | $30.77M | $11.35M |
Cash at Beginning of Period | $5.06M | $7.05M | $24.95M | $6.91M | $25.86M | $72.22M | $120.47M | $140.22M | $177.22M | $140.68M | $178.90M | $183.21M | $165.96M | $164.45M | $77.31M | $55.90M | $55.12M | $30.77M | $11.35M | $10.12M |
Operating Cash Flow | $-18.80M | $-9.47M | $-17.57M | $-21.69M | $-23.39M | $-23.37M | $-32.91M | $-22.30M | $-23.54M | $-21.17M | $-31.05M | $-22.45M | $-12.95M | $-19.11M | $-21.06M | $-13.91M | $-15.29M | $-10.04M | $-9.33M | $-6.71M |
Capital Expenditure | $-9.00K | $1.77K | $-108.00K | $-355.65K | $-1.81M | $-1.84M | $-3.80M | $-4.67M | $-8.82M | $-14.44M | $-20.22M | $-25.62M | $-7.75M | $-1.43M | $-505.00K | $-4.53M | $-4.02M | $-14.00K | $- | $-5.00K |
Free Cash Flow | $-18.81M | $-9.92M | $-17.68M | $-22.04M | $-25.20M | $-25.21M | $-36.71M | $-26.97M | $-32.35M | $-35.61M | $-51.26M | $-48.07M | $-20.70M | $-20.54M | $-21.56M | $-18.45M | $-19.30M | $-10.05M | $-9.33M | $-6.72M |
Tonix Pharmaceuticals Holding Stock Forecast
Analyst ratings, price targets, and earnings estimates for TNXP.
TNXP Analyst Ratings
Strong Buy
Based on 5 analysts in the past 3 months
Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Latest Price Target Updates
Date | Analyst | Firm | Price Target | Price When Posted | Upside |
---|
Tonix Pharmaceuticals Holding Dividends
Explore Tonix Pharmaceuticals Holding's dividend history, including dividend yield, payout ratio, and historical payments.
Peers: Biotechnology
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
---|---|---|---|---|---|
![]() Sonnet BioTherapeutics Holdings, Inc.
SONN
|
$4.94M | $1.62 | $-11.35 | $-0.59 | $-9.02 |
![]() Onconova Therapeutics, Inc.
ONTX
|
$20.90M | $1.00 | $-0.90 | $-21.88 | $38.84 |
![]() Palisade Bio, Inc.
PALI
|
$3.52M | $1.27 | $-26.97 | $-0.33 | $0.36 |
![]() iBio, Inc.
IBIO
|
$35.54M | $3.62 | $-6.50 | $-0.31 | $0.36 |
![]() Jaguar Health, Inc.
JAGX
|
$9.92M | $0.84 | $-107.42 | $-0.03 | $0.23 |
![]() Acasti Pharma Inc.
ACST
|
$34.17M | $3.37 | $-1.35 | $-2.56 | $0.53 |
![]() Diffusion Pharmaceuticals Inc.
DFFN
|
$8.98M | $4.40 | $-0.82 | $-9.35 | $2.75 |
![]() Vaxart, Inc.
VXRT
|
$162.72M | $0.72 | $-0.57 | $-1.01 | $1.44 |
![]() VBI Vaccines Inc.
VBIV
|
$1.87M | $0.07 | $-5.96 | $-0.10 | $1.22 |
![]() Bright Minds Biosciences Inc.
DRUG
|
$283.75M | $40.60 | $0.00 | $0.00 | $0.00 |
![]() Virax Biolabs Group Limited
VRAX
|
$8.42M | $1.94 | $-3.36 | $-0.22 | $0.27 |
![]() Novavax, Inc.
NVAX
|
$1.33B | $8.31 | $-5.41 | $-0.89 | $-0.67 |
![]() Inovio Pharmaceuticals, Inc.
INO
|
$71.12M | $1.97 | $-6.09 | $-1.00 | $1.16 |
![]() Enveric Biosciences, Inc.
ENVB
|
$3.61M | $1.65 | $-0.01 | $-2434.79 | $21.52 |
![]() CohBar, Inc.
CWBR
|
$1.19M | $0.41 | $-4.13 | $-0.41 | $0.32 |
Related Metrics
Explore detailed financial metrics and analysis for TNXP.